Search

Displaying results 3101 - 3110 of 7603 in total
  1. Drug

    Alclometasone

    go.drugbank.com/drugs/DB00240
    Approved

    Alclometasone is synthetic glucocorticoid steroid for topical use in dermatology as anti-inflammatory, antipruritic, antiallergic, antiproliferative and vasoconstrictive agent.

  2. Drug

    INO-4800

    go.drugbank.com/drugs/DB15693
    Investigational

    INO-4800 is a DNA vaccine containing the full sequence for the SARS-CoV-2 Spike (S) protein in development for immunization against COVID-19. … [A214475] A Phase 1 clinical trial for INO-4800 in the U.S. (NCT04336410) was started on April 3, 2020, with an expected completion date of July 2021.

    Categories: Experimental Unapproved Treatments for COVID-19
  3. Drug

    Linerixibat

    go.drugbank.com/drugs/DB11729
    ApprovedInvestigational

    [A275481, A275482] On March 19, 2026, linerixibat was approved by the FDA for the treatment of cholestatic pruritus in patients with primary biliary cholangitis (PBC).

  4. Drug

    SC12267

    go.drugbank.com/drugs/DB05125
    Investigational

    SC12267 is a novel, small molecule agent from the class of DMARDs (disease modifying anti-rheumatic drug) for the therapy of autoimmune diseases such as rheumatoid arthritis or multiple sclerosis. … Through highly selective inhibition of pyrimidine biosynthesis, it controls the growth of rapidly proliferating cells, especially of lymphocytes, which are important for the immune response.

  5. Drug

    Metergoline

    go.drugbank.com/drugs/DB13520
    Approved

    Metergoline is an ergot-derived psychoactive drug that acts as a ligand for serotonin and dopamine receptors. … [A27181] Its use has been studied in various clinical settings such as a treatment for seasonal affective disorder, prolactin hormone regulation due to its inhibitory effect on prolactin release,[A27182

    Categories: Heterocyclic Compounds with 4 or More Rings
  6. Drug

    Arbekacin

    go.drugbank.com/drugs/DB06696
    Investigational

    Often used for treatment of multi-resistant bacterial infection such as methicillin-resistant _Staphylococcus aureus_ (MRSA).

    Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic Use
  7. Drug

    Atrasentan

    go.drugbank.com/drugs/DB06199
    ApprovedInvestigational

    to be approved for this condition. … [L52855] In April 2025, atrasentan was granted accelerated approval by the FDA for the reduction of proteinuria in patients with primary IgA nephropathy, becoming the first endothelin A receptor antagonist

  8. Drug

    Imexon

    go.drugbank.com/drugs/DB05003
    Investigational

    Imexon is currently being studied for the treatment of pancreatic, lung, breast, prostate, melanoma, and multiple myeloma cancers. It belongs to the family of drugs called cyanoaziridine derivatives.

  9. Drug

    Capivasertib

    go.drugbank.com/drugs/DB12218
    ApprovedInvestigational

    [A262021,A262026,A262031] On November 17th, 2023, capivasertib, under the brand name TRUQAP, was approved by the FDA for the treatment of adult patients HR-positive, HER2-negative locally advanced or … Therefore, targeting the PIK3/AKT pathway presents a promising approach for the treatment of breast cancer, leading to the development of capivasertib, a pan-AKT kinase inhibitor.

  10. Drug

    Thymalfasin

    go.drugbank.com/drugs/DB04900
    Investigational

    Thymosin alpha 1 is now approved in 35 developing countries for the treatment of Hepatitis B and C. It is also used to boost the immune response in the treatment of other diseases.